We focus on the availability of advanced technologies for the treatment of autoimmune, oncological, cardiac and infectious diseases through the widespread use of personalized approaches.
Personalized medicine is a new unicorn that requires broad cooperation and efficient application of resources based on standard solutions, allowing innovative companies to focus on R&D, avoiding the cost of patchwork automation of standard operations. The availability of standard solutions, professionals and computing power will create momentum for the rapid development of advanced technology companies.
InUnio creates a favorable environment for the development of innovative medical, pharmaceutical and biotechnology companies.
Data is always at the heart of the idea generation process. InUnio allows you to get access to data that will enable a continuous flow of idea generation in various fields.
Only 10% of ideas get tested. A data-tested hypothesis allows more resources to be mobilized for implementation.
Not every tested hypothesis is economically viable for implementation at a given time.
Clinically Proven Treatment complies with domestic and international standards and will attract more audience (doctors and patients).
For the implementation of treatment "on stream" it is necessary to develop and implement a significant resource base.
Having a clinically proven treatment and a resource base that allows for this treatment, it is possible to move on to the introduction of this treatment in private and public clinics, including with the involvement of insurance companies for inclusion in compulsory medical insurance / VHI.
ПGlobal treatment allows you to accumulate more data, which in the future will allow you to start this cycle anew.
System combines resource aggregators (sequencing, mass spectrometry, chromatography, peptide synthesis, etc.), bioinformaticians, IT companies, modern research centers and vivariums, research organizations, pharmaceutical and biotech start-ups for efficient work with other counterparties for long-term operations and integrated logistics.
Contains ready-made software modules for analysis of omics data, biobanking, data processing from equipment, interpretation of the application of reagents, management of bioinformatics protocols, research management and laboratory operations, quality control, integration of data from various sources (open databases, data from equipment, third party ICs).
A library of components and drivers for interacting with heterogeneous databases and equipment.
What is it: systems for storing and analyzing big medical data, including omics data and phenotypic data from medical information systems, medical images, etc.
Existing solutions: The Cancer Genome Atlas, DNANexus, Seven Bridges.
What it is: Production of vaccines that affect pre-selected cells.
Specialists: surgery, histology, bioinformatics, sequencing equipment, mass spectrometry, peptide synthesis.
Key factors: the quality of the neoantigen evaluation algorithm, the purity of the obtained peptides (for peptide vaccines), the production rate.
Facts: Neoantigen vaccines in combination with various adjuvants have shown a significant improvement in the prognosis for diseases such as melanoma, glioblastoma, breast cancer and several others. https://pubmed.ncbi.nlm.nih.gov/35214655/
Existing solutions: SAP Ariba, IQVIA, Boston Gene, Insilco Medicine.
What it is: The process of profiling tumors in various implementations involves the collection of genomic material, processing and interpretation of the results based on information from a variety of databases with a heterogeneous structure and degree of completeness.
Specialists in the fields of: surgery, histology, sequencing, logistics, bioinformatics, access to high-quality reagents and sequencing equipment.
What it is: Production of turnkey laboratory analyzes will reduce the cost of analysis, which will open up the personalized medicine market for a large number of users and improve the quality of treatment by selecting drugs based on individual characteristics.
Key success factors: High-quality reagents, user-friendly software, high-performance algorithms.
Existing solutions: Roche, Agilent, Shimadzu, GE, Waters.
What it is: A quick search for information about the causal relationships of gene variants and their combinations with the conditions of patients, modes of inheritance to assess the risks of diseases.
Topics include the creation of extensible diagnostic panels to detect genomic, transcriptomic or proteomic disorders associated with diseases such as coronary heart disease, strokes, atherosclerosis, long QT syndrome, hypertension and cardiomyopathy of various types, the creation of result interpretation environments using a variety of public databases and articles.
What it is: Creation of immunological profiles of patients to determine the exact dosage and selection of drugs, taking into account genetic characteristics.
Specialists: medicine, chemistry, bioinformatics, molecular biology, use of cell sorting equipment, sequencing, as well as software for data integration and presentation of results.
What it is: InUnio allows you to save, manage and process laboratory and clinical data in accordance with the requirements of Russian legislation.
Key success factors - import substitution of foreign software.
Facts: The volume of expenses for the acquisition of licenses in 2019-2021 amounted to 2.5 billion rubles. In view of the active import substitution, InUnio acts as an analogue of this software.
Existing import solutions: Waters Empower, Mettler Toledo, Testo, Bruker, BIO-RAD, Sartorius, Labware, Agilent, Veeva, Medidata, Open Clinic.
Learn about advanced methods of treatment and prevention of diseases, take part in their testing and testing.
Increase speed and quality while reducing cost and time of R&D.
Increase the utilization of equipment and personnel, including through international cooperation.
Get access to orders and instruments (data brokers, storage and data processing algorithms) in a high potential for income increase area.
Identify areas with high revenue potential, as well as promising means and methods for commercialization.
Contact us